Maxim Group Reiterates Hold Rating for Theriva Biologics (NYSEAMERICAN:TOVX)

Theriva Biologics (NYSEAMERICAN:TOVX)‘s stock had its “hold” rating reissued by stock analysts at Maxim Group in a research note issued to investors on Thursday, MarketBeat.com reports.

Theriva Biologics Stock Down 17.6 %

Shares of Theriva Biologics stock opened at $0.53 on Thursday. The firm has a market cap of $1.47 million, a PE ratio of -0.02 and a beta of 1.22. Theriva Biologics has a 52 week low of $0.47 and a 52 week high of $10.75. The business’s fifty day simple moving average is $1.22 and its 200-day simple moving average is $1.62.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.